Breaking News Instant updates and real-time market news.

MYGN

Myriad Genetics

$18.63

0.01 (0.05%)

14:00
10/17/16
10/17
14:00
10/17/16
14:00

Myriad jumps after saying it will present four new studies at ASHG

Earlier today, Myriad Genetics announced it will present four new studies at the American Society of Human Genetics Annual Meeting being held Oct. 18-22 in Vancouver, British Columbia. The research being presented highlights the clinical utility of Myriad's myVision Variant Classification Program and myRisk Hereditary Cancer gene panel test. "Precision medicine is dependent on the accuracy of the information being provided to patients, and Myriad's myVision is the most advanced variant classification program available to determine whether a patient's genetic mutation is benign or deleterious," said Johnathan Lancaster, M.D., Ph.D, chief medical officer, Myriad Genetic Laboratories. "At ASHG, we are excited to present four new studies, which advance the state of the art of genetic testing and meet the scientific needs of researchers and clinicians." shares of Myriad Genetics are up 87c or 4.65% to $19.50 per share.

MYGN Myriad Genetics
$18.63

0.01 (0.05%)

08/29/16
BOFA
08/29/16
NO CHANGE
BOFA
Myriad Genetics loses BCBS of Nevada contract to LabCorp, says BofA/Merrill
Analysts at BofA Merrill Lynch noted that Myriad Genetics (MYGN) has lost an in-network contract with Blue Cross Blue Shield of Nevada to LabCorp (LH) and the firm expects Myriad shares to trade down following the news. The firm sees the potential for a continuation of this trend across other BCBS systems in other states.
10/10/16
LTCO
10/10/16
DOWNGRADE
Target $16
LTCO
Sell
Myriad Genetics downgraded to Sell from Neutral at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Myriad Genetics (MYGN) to Sell citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. The analyst expects a lower growth outlook to drive "significant P/E multiple compression." Tesaro (TSRO) presented data this weekend that suggested its PARP inhibitor niraparib was active in a maintenance setting for recurrent ovarian cancer in patients with either positive or negative HRD scores. The analyst had expected the drug to benefit only HRD positive patients. As such, the use of niraparib will not require HRD testing, DeGeeter tells investors in a research note. The analyst has a $16 price target for the shares.
10/10/16
PIPR
10/10/16
NO CHANGE
PIPR
Neutral
TESARO data suggest Myriad test not necessary, says Piper Jaffray
Piper Jaffray analyst William Quirk points out that data over the weekend from TESARO (TSRO), Myriad Genetics' (MYGN) companion diagnostic partner, suggest niraparib works in all-comers, making Myriad's test not necessary. Myriad shares may be down physiologically, Quirk tells investors in a research note partially titled "When A Partnership Produces Mixed Results." The analyst, however, believes niraparib is not clinically significant in HRD negative patients and that Myriad's test will be included on the drug label. He keeps a Neutral rating on shares of Myriad. Ladenburg Thalmann this morning downgraded the stock to Neutral.
10/10/16
10/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Honeywell (HON) downgraded to Buy from Conviction Buy at Goldman with analyst Christopher Glynn lowering his Q3 Earnings Per Share expectations for Honeywell after the company cut its earnings and revenue outlook and trimmed his price target to $122 from $128. 2. United Technologies (UTX) downgraded to Neutral from Buy at Citi with analyst Jason Gursky saying he sees three issues limiting share upside over the next twelve-plus months. 3. PNC Financial (PNC) was downgraded to Neutral from Buy at Nomura while the firm downgraded Fifth Third (FITB) to Reduce from Neutral. 4. Myriad Genetics (MYGN) downgraded to Sell from Neutral at Ladenburg with analyst Kevin DeGeeter citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. 5. HSN, Inc. (HSNI) downgraded to Hold from Buy at Craig-Hallum with analyst Alex Fuhrman saying his channel checks indicate continued weakness in the third quarter, with particular weakness in jewelry and consumer electronics. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AYI

Acuity Brands

$161.46

3.9 (2.48%)

21:35
09/20/18
09/20
21:35
09/20/18
21:35
Upgrade
Acuity Brands rating change at Wells Fargo »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

TTNP

Titan Pharmaceuticals

$0.50

-0.08 (-13.79%)

21:34
09/20/18
09/20
21:34
09/20/18
21:34
Syndicate
Titan Pharmaceuticals raises $9.5M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MTEM

Molecular Templates

$5.81

-0.44 (-7.04%)

21:31
09/20/18
09/20
21:31
09/20/18
21:31
Syndicate
Molecular Templates 8.2M share Secondary priced at $5.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

YMAB

Y-mAbs Therapeutics

$0.00

(0.00%)

21:30
09/20/18
09/20
21:30
09/20/18
21:30
Syndicate
Y-mAbs Therapeutics 6M share IPO priced at $16.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

VKTX

Viking Therapeutics

$18.92

-0.72 (-3.67%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Viking Therapeutics 9.5M share Secondary priced at $18.50 »

William Blair, SunTrust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

TWIN

Twin Disc

$23.33

0.34 (1.48%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Twin Disc 1.333M share Secondary priced at $22.50 »

Baird and Oppenheimer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

FTCH

Farfetch

$0.00

(0.00%)

21:26
09/20/18
09/20
21:26
09/20/18
21:26
Syndicate
Farfetch 44.244M share IPO priced at $20.00, above the range »

Goldman Sachs, JPMorgan,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

CRSP

Crispr Therapeutics

$48.90

-3 (-5.78%)

21:25
09/20/18
09/20
21:25
09/20/18
21:25
Syndicate
Crispr Therapeutics 4.211M share Secondary priced at $47.50 »

Goldman Sachs, Piper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 21

    Sep

MDCA

MDC Partners

$4.55

0.25 (5.81%)

21:08
09/20/18
09/20
21:08
09/20/18
21:08
Hot Stocks
MDC Partners to evaluate strategic alternatives »

MDC Partners announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWRE

Guidewire

$101.71

0.16 (0.16%)

20:27
09/20/18
09/20
20:27
09/20/18
20:27
Hot Stocks
Guidewire sees 5-year target revenue of about $1.3B »

Sees % subscription of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

AVMXY

Avita Medical

$0.00

(0.00%)

20:13
09/20/18
09/20
20:13
09/20/18
20:13
Hot Stocks
Avita Medical announces FDA approval of RECELL in burn treatment »

AVITA Medica announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.36

-0.03 (-1.26%)

20:05
09/20/18
09/20
20:05
09/20/18
20:05
Hot Stocks
Ladenburg Thalmann CEO to serve as chairman »

Ladenburg Thalmann…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

19:25
09/20/18
09/20
19:25
09/20/18
19:25
Conference/Events
Morgan Stanley multi-industrial analysts hold analyst/industry conference call »

U.S. Electrical Equipment…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

, SPX

S&P 500

$0.00

(0.00%)

19:15
09/20/18
09/20
19:15
09/20/18
19:15
General news
Trump's former lawyer Cohen met with Mueller multiple times, ABC says »

President Donald…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCS

Steelcase

$16.10

0.8 (5.23%)

, ACAD

Acadia

$19.08

3.97 (26.27%)

19:09
09/20/18
09/20
19:09
09/20/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SCS

Steelcase

$16.10

0.8 (5.23%)

ACAD

Acadia

$19.08

3.97 (26.27%)

TXN

Texas Instruments

$108.50

1.14 (1.06%)

MCD

McDonald's

$160.84

1.65 (1.04%)

RDS.A

Royal Dutch Shell

$66.83

0.57 (0.86%)

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

UNFI

United Natural Foods

$33.83

0.54 (1.62%)

MU

Micron

$46.06

1.01 (2.24%)

SGH

Smart Global

$30.44

0.7 (2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 01

    Oct

  • 04

    Oct

  • 10

    Oct

  • 28

    Oct

KORS

Michael Kors

$72.72

-0.33 (-0.45%)

19:01
09/20/18
09/20
19:01
09/20/18
19:01
Hot Stocks
Michael Kors names Andrea Pesaresi head of Men's business »

Michael Kors Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

19:00
09/20/18
09/20
19:00
09/20/18
19:00
Hot Stocks
Medtronic to acquire Mazor Robotics for $58.50 per ADS, or about $1.64B »

Medtronic (MDT) and Mazor…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

18:59
09/20/18
09/20
18:59
09/20/18
18:59
Hot Stocks
Breaking Hot Stocks news story on Medtronic, Mazor Robotics »

Medtronic to acquire…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:54
09/20/18
09/20
18:54
09/20/18
18:54
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:48
09/20/18
09/20
18:48
09/20/18
18:48
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SONA

Southern National Bancorp

$16.89

0.13 (0.78%)

18:45
09/20/18
09/20
18:45
09/20/18
18:45
Hot Stocks
Southern National Bancorp names Jeffrey Karafa CFO »

Southern National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$298.32

-0.63 (-0.21%)

18:44
09/20/18
09/20
18:44
09/20/18
18:44
Periodicals
Tesla VP of global supply management O'Connor to leave company, Bloomberg says »

Liam O'Connor,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

  • 29

    Oct

CRBP

Corbus Pharmaceuticals

$7.90

2.75 (53.40%)

18:34
09/20/18
09/20
18:34
09/20/18
18:34
Hot Stocks
Corbus CEO says wants to be leading pipeline for synthetic endocannabinoids »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 01

    Oct

MCD

McDonald's

$160.84

1.65 (1.04%)

18:32
09/20/18
09/20
18:32
09/20/18
18:32
Hot Stocks
McDonald's says dividend hike reinforces confidence in long-term targets »

McDonald's says the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

MCD

McDonald's

$160.84

1.65 (1.04%)

18:31
09/20/18
09/20
18:31
09/20/18
18:31
Hot Stocks
McDonald's raises quarterly dividendy by 15% to $1.16 per share »

McDonald's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.